1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration
1979
Chemotherapy of Hodgkin's disease
Young R, DeVita V. Chemotherapy of Hodgkin's disease. Clinics In Haematology 1979, 8: 625-644. PMID: 91466, DOI: 10.1016/s0308-2261(79)80007-7.Peer-Reviewed Original ResearchConceptsAdvanced diseaseHodgkin's diseaseModality approachSuch long-term complicationsIIIB Hodgkin's diseaseInduction chemotherapy regimensPrimary induction failureShort initial remissionAdvanced Hodgkin's diseaseDisease-free survivalOverall survival ratePrognosis of patientsLong-term complicationsInduction failureAggressive therapyChemotherapy regimensComplete remissionInitial remissionLate complicationsSecond malignanciesCombination chemotherapySurvival benefitMOPP regimenActual survivalCombined modality